5002Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial. (28th August 2018) - Sever, P S; Gouni-Berthold, I; Keech, A; Giugliano, R; Pedersen, T; Wasserman, S; Im, K; Sabatine, M; O'Donoghue, M; ,